SCHEMBL17001673

SCHEMBL17001673

COCCNC(=O)N1CCCC1C1CCN(C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.45
▸ ATM Q13315 1/20 0.45
▸ HCRTR2 O43614 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ HPGD P15428 3/20 0.40
▸ TDP1 Q9NUW8 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ OPRM1 P35372 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ MTNR1A P48039 2/20 0.36
▸ MTNR1B P49286 2/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ ASAH1 Q13510 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18382061 1.00 KDM4E (0.45) KDM4EATMHCRTR2SMN1; SMN2NPC1
SCHEMBL17001664 0.84 NPC1 (0.44) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
SCHEMBL17001680 0.82 NPC1 (0.47) HCRTR2SMN1; SMN2NPC1RAB9ATDP1
SCHEMBL17001713 0.80 SMN1; SMN2 (0.48) KDM4ESMN1; SMN2NPC1RAB9ATDP1
SCHEMBL17001690 0.80 SMN1; SMN2 (0.48) KDM4ESMN1; SMN2NPC1RAB9ATDP1
SCHEMBL20310809 0.78 L3MBTL3 (0.37) KDM4EATMSMN1; SMN2NPC1RAB9A
SCHEMBL17001687 0.78 L3MBTL3 (0.37) KDM4EATMSMN1; SMN2NPC1RAB9A
SCHEMBL18382159 0.77 NPC1 (0.43) HCRTR2SMN1; SMN2NPC1RAB9ATDP1
SCHEMBL17001677 0.77 NPC1 (0.43) HCRTR2SMN1; SMN2NPC1RAB9ATDP1
SCHEMBL18382059 0.77 NPC1 (0.43) KDM4ESMN1; SMN2NPC1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10385039-B2 Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-08-20 — — US disclosed
US-20190112294-A1 BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS NXERA PHARMA UK LIMITED (GB) 2019-04-18 — — US disclosed
US-20180179184-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-28 — — US disclosed
US-20180179184-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-28 — — US disclosed
WO-2015118342-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. HEPTARES THERAPEUTICS LIMITED (GB) 2015-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190112294-A1 BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM5 KDM4E 809/4885ATM 3574/4885HCRTR2 226/4885
US-10385039-B2 Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists CHRM1, CHRM2, CHRM5 KDM4E 809/4885ATM 3574/4885HCRTR2 226/4885
US-20180179184-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 KDM4E 1045/4885ATM 2556/4885HCRTR2 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback